SARS-CoV-2 PLpro Inhibitors (IMAGE) Compuscript Ltd Caption This study compared the potency of a collection of SARS-CoV-2 PLpro inhibitors and identified the most potent compound GRL-0617 with the IC50=2.2 μmol/L. Subsequently, the authors revealed the binding mode of GRL-0617 with the protease using crystallographic approach, providing a framework for further inhibitor development targeting SARS-CoV-2 PLpro. Credit Acta Pharmaceutica Sinica B Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.